Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia

Immune Thrombocytopenia Clinical Trial

— RITUX PLUS  

Official title:

RITUX-PLUS. A Prospective Open Trial to Assess the Efficacy and Safety of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03154385
• Other study ID #: P130408
• Status: Completed
• Phase: N/A
• Start date: March 13, 2017
• Est. completion date: November 13, 2019

Study information

• Verified date: February 2020
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous studies have shown that increase level of BAFF could promote the settlement of long-lived plasma cells in the spleen of ITP patients treated with anti-CD20. This single-center prospective pilot study, currently in phase IIa, will evaluate the efficacy of a rituximab and belimumab sequential combination treatment. Investigators plan to include 15 patients with persistent ITP over a 24-month inclusion period. Each patient will be followed for 1 year

Description:

This single-center prospective pilot study, currently in phase IIa, evaluates the efficacy of a rituximab and belimumab sequential combination treatment. Based on the Fleming method, this study scheme includes a single step method.

Eligible patients, having given consent and having been verified for inclusion criteria, will receive two intravenous perfusions of 1 g of Rituximab (Mabthera ®) at W0 and W2 coupled with 100 mg intravenous methylprednisone to avoid potential allergic reactions.

Five belimumab (Benlysta ®) injections will be administered (W0 + 2days, W2 + 2 days, W4, W8, W12) at 10mg/kg doses. The first two injections are administered 2 days after Rituximab perfusions. The adopted experimental scheme was once used to show use of belimumab in systemic lupus erythematosus in accordance with AMM regulation.

This phase II prospective single-center open-trial will be conducted at the National Referral Center for Adult Immune Cytopenia located in the Henri Mondor University Hospital. Investigators plan to include 15 patients with persistent ITP over an 24-month inclusion period. Each patient will be followed for 1 year

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: November 13, 2019
• Est. primary completion date: November 13, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years, <75 years

• Primary ITP diagnostic defined according to the standard definition criteria (Rodeghiero et al Blood 2008)

• Previous transient response to first-line treatments of corticosteroids and/or IgIV characterized by a rise of platelet levels > 30 G/L with at least a twofold increase from baseline levels followed by a relapse.

• Platelet count = 30,000 /µL at inclusion or <50 G/L if presence of hemorrhagic events or other reason left up to investigator discretion.

• A persistent ITP active and existing for more than 3 months but less than 5 years from diagnosis.

• Normal Bone marrow smear for patients above 60 years of age

• Negative pregnancy test results for women of procreation age

• Gammaglobulin level > 7 g/L

• Informed consent

Exclusion Criteria:

• Splenectomy

• Previous treatment by Rituximab or any B-cell targeted therapy

• Previous treatment by cyclophosphamide

• No medical treatments of a therapeutic protocol nature within the last 30 days

• Previous anaphylactic shock

• Previous septic shock or severe sepsis

• Chronic and ongoing severe infection requiring treatment or hospitalization in the 60 days preceding inclusion.

• Severe acute infection within the last 4 weeks

• Use of parenteral antibiotics within 60 days current use of suppressive therapy for chronic infection such as tuberculosis, pneumocystis, cytomegalovirus, HSZ, herpes zoster, and atypical mycobacteria

• History of primary immunodeficiency, IgG level < 400 mg/dl and/or IgA level < 10 mg/dl

• Have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months or who in the investigator's judgment, pose a significant suicide risk.

• Secondary ITP

• History of recurrent infections

• Neutrophils count < 1,000/mm3 at inclusion

• Positive HIV test and/or hepatitis virus C infection and/or positive hepatitis B virus surface antigen or core antibody (HbsAg or HBcAb)

• Impaired renal function as indicated by a serum creatinine level > 2 mg/dl

• New York Heart Classification III or IV heart disease

• Treatment by antiaggregant/antiplatelet or anti-vitamin K drug

• Previous history of malignancy in the last 5 years other than cutaneous carcinoma

• Previous history of severe psychiatric disorder or previous suicide attempts in the last 6 months or suicidal thoughts in the last 2 months leading up to inclusion

• Unable to comply with study and follow-up procedures due to psychiatric disorders or any other reason

• Alcohol or drug abuse or dependence, either current or within 1year

• Pregnancy or Breast-Feeding

• Live, attenuated vaccinations must be administered at least 30 days before inclusion in study

• History of significant medical illness or clinically significant laboratory abnormality (or planned surgical procedure) which in the opinion of the investigator would interfere with the study procedures and / or assessments or compromise subject safety

Related Conditions & MeSH terms

• Immune Thrombocytopenia
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Drug:
• Rituximab (Mabthera ®) Belimumab (Benlysta ®)
Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12

Locations

Country	Name	City	State
France	Henri Mondor Hospital	Creteil

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The total number of patient responses to treatment, in other words sum of complete responses + responders	A responder (R) to treatment is defined by a patient with a maintained platelet count at >30x109/L (Rodeghiero et al Blood 2008) and a minimum twofold increase from initial platelet levels in the absence of bleeding and/or use of ITP directed therapies between Week 6 and Week 52 of patient follow-up.; A complete response (CR) is defined by a platelet count > 100 x 109/L maintained in the absence of any other ITP directed therapies between Week 6 and Week 52.; A Non-Responder (NR) is a patient with one or all of the following : Platelet count less than < 30 x 109/L by the end of study; Require a rescue therapy (a new course of corticosteroids and/or intravenous immunoglobulin) more than 6 weeks after inclusion.; Underwent any other treatment for ITP over the study period	Week 52
Secondary	Number of patients developing a severe hypogammaglobulinemia (gammaglobulin level < 4 g/dl)		at weeks 12, 24, 36, and 52
Secondary	Evolution of gammaglobulin levels		at weeks 4, 8, 12, 24, 36, and 52
Secondary	Duration of severe hypogammaglobulinemia in patients with such complication		Week 24
Secondary	Variation in gammaglobulin subclass levels throughout the study		at weeks 0,12, 24, 36, 52
Secondary	Number of severe infections requiring hospitalization		at weeks 24, 36 and 52
Secondary	Platelet Levels		at weeks 4, 8, 12, 24, 36, and 52
Secondary	Total number of responders (responders + complete responses)		at weeks 12,25, and 36